|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. James C. Mullen||Chairman, Pres & CEO||100,5k||N/D||1959|
|Ms. Michelle Robertson||CFO, Principal Accounting Officer, Treasurer & Assistant Sec.||647,26k||N/D||1967|
|Dr. Lisa A. Michaels M.D.||Exec. VP & Chief Medical Officer||213,47k||N/D||1965|
|Dr. Feng Zhang||Co-Founder & Scientific Advisory Board Member||N/D||N/D||N/D|
|Dr. George McDonald Church Ph.D.||Co-Founder & Scientific Advisory Board Member||N/D||N/D||1954|
|Dr. J. Keith Joung M.D., Ph.D.||Co-Founder & Scientific Advisory Board Member||N/D||N/D||N/D|
|Dr. David R. Liu Ph.D.||Co-Founder & Scientific Advisory Board Member||N/D||N/D||N/D|
|Mr. Harry R. Gill III||Sr. VP of Operations||N/D||N/D||1961|
|Dr. Mark S. Shearman||Exec. VP & Chief Scientific Officer||N/D||N/D||1960|
|Ron Moldaver||Investor Relations||N/D||N/D||N/D|
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
L'ISS Governance QualityScore di Editas Medicine, Inc. al 26 settembre 2021 è 8. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.